Genentech, Inc.

F. Hoffmann-la Roche Ag

Pharmacyclics, Inc.

Hoffmann-la Roche Inc.

Genetech, Inc.

Signature Therapeutics, Inc.

Axys Pharmaceuticals, Inc.

Aleksandr Kolesnikov

Steven Huy Do

Alan G Olivero

Adrian Folkes

Steven T Staben

Chudi Obioma Ndubaku

Stephen Colin Price

Robert Andrew Heald

Timothy Heffron

Nicole Blaquiere

Danette Dudley

Richard A Goldsmith

Wendy B Young

William Dvorak Shrader

Roopa Rai

Bing-Yan Zhu

Daniel P Sutherlin

Kieron E Wesson

Michael Siu

Xiaojing Wang

Jianwen A Feng

Thomas E Jenkins

Brian Salvatore Safina

Wendy Lee

BinQing Wei

Birong Zhang

James John Crawford

Vickie H Tsui

Kwong Wah Lai

Joseph P Lyssikatos

Anthony A Estrada

Huifen Chen

Jun Liang

Vickie Hsiao-Wei Tsui

Po-Wai Yuen

Erik Joel Verner

Matthew Volgraf

Vishal Verma

Elisia Villemure

Lan Wang

Mark Jones

Tim Heffron

Tracy Bayliss

Steven M Torkelson

Paul Goldsmith

Neil Pegg

Huiyong Hu

Naomi S Rajapaksa

Binqing Wei

Joy Drobnick

Steven McKerrall

Marian C Bryan

Daniel Shore

Guosheng Wu

Aijun Lu

Zhaoyang Wen

James Richard Kiefer, Jr

Wenfeng Liu

Steven Do

Alberto Gobbi

Baihua Hu

Richard L Mackman

Xingyu Lin

Yanyan Chu

Spencer R Jeffrey

Darin A Allen

Jason M Hataye

Witold N Hruzewicz

Adrian J Folkes

Stephen Price

Steven Staben

Robert Heald

Chudi Ndubaku

The invention provides a compound of formula (I):

Therapeutic compounds and methods of use thereof

Compounds of Formula I and methods of use as Interleukin-1 Receptor Associated Kinase 4 (IRAK4) inhibitors are described herein.

Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators

Compounds having the formula I wherein R, X, X, Xand Xas defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders. 

Serine/threonine kinase inhibitors

The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators

Compounds of Formula 0, Formula I, and Formula II and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R, R, R, R, and Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The invention relates to compounds of formula (I): 

2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use

The invention relates to compounds of formula (I): wherein Q, A, A, A, A, A, A, A, R, Rand Rare as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein Rand Rare as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pyrazolo[3,4-c]pyridine compounds and methods of use

Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Zis CRor N; Zis CRor N; Zis CRor N; Zis CRor N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Benzoxazepin PI3K inhibitor compounds and methods of use

Growing community of inventors

San Francisco, CA, United States of America

Aleksandr Kolesnikov